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Objectives. This study sought to investigate the influence of
right ventricular (RV) hemodynamic variables and function on
the secretion of brain natriuretic peptide (BNP) in patients with
isolated RV overload.
Background. Plasma BNP is known to increase in proportion to
the degree of left ventricular (LV) overload. However, whether
BNP secretion is also regulated in the presence of RV overload
remains unknown.
Methods. Plasma BNP and atrial natriuretic peptide (ANP)
levels in the pulmonary artery were measured in 44 patients with
RV overload: 18 with RV volume overload (RVVO) due to atrial
septal defect and 26 with RV pressure overload (RVPO) due to
primary or thromboembolic pulmonary hypertension. Right heart
catheterization was performed in all patients. RV and LV ejection
fraction, myocardial mass and volume of the four chambers were
determined by using electron beam computed tomography.
Results. Although both plasma BNP and ANP levels were
significantly elevated in patients with RV overload compared with
values in control subjects, plasma BNP and the BNP/ANP ratio
were significantly higher in patients with RVPO than with RVVO
(BNP 294 6 72 vs. 48 6 14 pg/ml; BNP/ANP 1.6 6 0.2 vs. 0.8 6
0.2, both p < 0.05). Plasma BNP correlated positively with mean
pulmonary artery pressure (r 5 0.73), total pulmonary resistance
(r 5 0.79), mean right atrial pressure (r 5 0.79), RV end-diastolic
pressure (r 5 0.76) and RV myocardial mass (r 5 0.71); it
correlated negatively with cardiac output (r 5 20.33) and RV
ejection fraction (r 5 20.71). Plasma BNP significantly decreased
from 315 6 120 to 144 6 54 pg/ml with long-term vasodilator
therapy (total pulmonary resistance decreased from 23 6 4 to
15 6 3 Wood U).
Conclusions. Plasma BNP increases in proportion to the extent
of RV dysfunction in pulmonary hypertension.
(J Am Coll Cardiol 1998;31:202–8)
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Brain natriuretic peptide (BNP) was first isolated from the
porcine brain (1) and was later found in the human heart (2).
BNP shares with atrial natriuretic peptide (ANP) a high degree
of structural homology and a profile of diuretic, natriuretic and
vasodilator activities and inhibition of the renin-angiotensin-
aldosterone system (3). Unlike ANP, however, plasma BNP
has as its main source the cardiac ventricles, suggesting that
BNP may be more sensitive and specific than ANP as an
indicator of ventricular disorders. Earlier studies have shown
that plasma BNP levels are increased in states of left ventric-
ular (LV) overload, such as LV failure (4) or LV hypertrophy
(5) and this can be a useful biochemical marker for LV
overload.
Regarding right ventricular (RV) overload, an experimen-
tal study (6) has shown that plasma BNP levels are elevated in
association with increased pulmonary hypertension in rats. In
humans, plasma ANP levels have been shown (7) to be
elevated in patients with pulmonary hypertension. However,
there has been no report regarding the modes of BNP secre-
tion in isolated RV overload, in part because the complicated
configuration of the RV has made it difficult to measure RV
volume and mass by conventional methods. Electron beam
computed tomography (CT) has made it possible to evaluate
RV volume and mass with a high degree of accuracy (8,9).
Thus, the purpose of this study was to use this method to
investigate the influence of RV hemodynamics and function on
the secretion of BNP in patients with RV overload.
Methods
Study patients. We studied 44 patients with isolated RV
overload (19 men and 25 women, mean age 47 years [range 20
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to 68]). Eighteen patients with atrial septal defect served as a
model of RV volume overload (RVVO) and 26 with pulmo-
nary artery hypertension (10 with primary pulmonary hyper-
tension and 16 with chronic thromboembolic pulmonary hy-
pertension) as a model of RV pressure overload (RVPO). The
diagnosis of atrial septal defect was made by echocardiography
and was confirmed by cardiac catheterization (10). All patients
had uncomplicated secundum atrial septal defect. No patient
had evidence of the Eisenmenger syndrome. Patients with
pulmonary valve stenosis were not included. Pulmonary artery
hypertension was defined by a mean pulmonary artery pressure
.25 mm Hg at rest (11). Primary pulmonary hypertension was
defined as pulmonary hypertension unexplained by any sec-
ondary cause, based on the criteria of National Institutes of
Health registry on primary pulmonary hypertension (11).
Chronic thromboembolic pulmonary hypertension was identi-
fied by radionuclide perfusion lung scans and pulmonary
angiography (12,13). All patients were in a steady state during
this study protocol. Patients with one or more of the following
conditions were excluded: 1) significant LV diseases, such as
primary myocardial, valvular or coronary artery disease; 2)
acute heart failure; 3) chronic renal impairment (serum creat-
inine $133 mmol/liter); and 4) sustained arrhythmia, such as
atrial fibrillation. The study included 11 age-matched control
subjects (5 men and 6 women, mean age 50 years [range 29 to
65]). All subjects provided written informed consent.
Hemodynamic studies. Right heart catheterization was
performed in all subjects after an overnight fast. The following
hemodynamic variables were obtained at end-expiration: mean
pulmonary artery pressure, mean right atrial pressure, RV
end-diastolic pressure, pulmonary capillary wedge pressure
and mean systemic arterial pressure. Cardiac output was
determined by the Fick method. Total pulmonary resistance
was calculated by dividing mean pulmonary artery pressure by
cardiac output. Control subjects demonstrated normal hemo-
dynamics by right heart catheterization. Pulmonary to systemic
flow ratio in patients with atrial septal defect was obtained by
the oximetric principle of Fick (10).
Electron beam CT. Ventricular and atrial volume and
myocardial mass were measured by using electron beam CT in
35 patients (14 of the 18 patients with RVVO and 21 of the 26
with RVPO) within 1 month of cardiac catheterization and
blood sampling. No changes in the clinical status or medication
regimens occurred between the CT and cardiac catheterization
studies. Three patients with primary pulmonary hypertension
and one with thromboembolic pulmonary hypertension were
excluded from the CT study because of severe RV dysfunction.
Four patients with atrial septal defect and one with thrombo-
embolic pulmonary hypertension rejected the protocol. Elec-
tron beam CT was performed with a C-150 scanner (Imatron),
as previously reported (14). In brief, cine mode scanning
(scanning time 50 ms for 256 matrix images) was performed
after the administration of 40 to 50 ml of nonionic contrast
medium (Iopamidol 370, Nippon Schering). The scanner table
was rotated 25° in a clockwise horizontal direction to obtain
near short-axis views of the heart. Eight-level (10 contiguous
images/level) or 10-level (8 contiguous images/level) cine mode
scans of the heart were obtained with electrocardiographic
(ECG) gating. The end-diastolic (R wave on the ECG) and
end-systolic (smallest ventricular chamber volume during the
cardiac cycle) frames were identified at each tomographic
level. Endocardial and epicardial borders of the ventricles were
determined by using previously described methods of edge
detection for electron beam CT (Fig. 1) (9).
We used a modified version of Simpson’s method to obtain
multisection cine mode scans and then calculated the following
variables: RV end-diastolic volume index, RV ejection frac-
tion, RV myocardial mass index, right atrial end-systolic
volume index, LV end-diastolic volume index, LV ejection
fraction, LV myocardial mass index and left atrial end-systolic
volume index.
Reproducibility of CT measurements (mean 6 SD) was
assessed in 10 subjects randomly allocated from the patients
with RVVO and RVPO. The mean differences between the
measurements in each subject were 2 6 1% for RV ejection
fraction and 3 6 3 ml/m2 for RV myocardial mass index.
Interobserver variability was also assessed in the same 10
subjects by two independent observers (N.N. and S.H.). The
mean differences between the measurements of the two ob-
servers were 3 6 2% for RV ejection fraction and 3 6 4 ml/m2
for RV myocardial mass index.
Abbreviations and Acronyms
ANP 5 atrial natriuretic peptide
BNP 5 brain natriuretic peptide
CT 5 computed tomography (tomographic)
ECG 5 electrocardiogram, electrocardiographic
LV 5 left ventricle (ventricular)
NO 5 nitric oxide
RV 5 right ventricle (ventricular)
RVPO 5 right ventricular pressure overload
RVVO 5 right ventricular volume overload
Figure 1. Typical short-axis tomogram at the mid-ventricular level in a
patient with primary pulmonary hypertension. The endocardial and
epicardial border lines of the RV cavity are drawn to calculate the RV
ejection fraction, volume and myocardial mass at the corresponding
level. See text for details.
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Blood sampling and assay for ANP and BNP. Blood sam-
ples were drawn simultaneously from the main pulmonary
artery and femoral vein during cardiac catheterization. Blood
was immediately transferred into chilled glass tubes containing
disodium EDTA (1 mg/ml) and aprotinin (500 U/ml); it was
centrifuged immediately at 4°C, and the plasma was frozen and
stored at 280°C until assayed. Plasma ANP and BNP levels
were measured directly with specific immunoradiometric assay
kits (Shiono RIA ANP assay kit and Shiono RIA BNP assay
kit, Shionogi Co., Ltd., Osaka, Japan) (4). Data analyses were
done on the samples from the main pulmonary artery unless
otherwise stated.
Effects of acute hemodynamic changes on plasma ANP and
BNP levels. Nitric oxide (NO) was inhaled by 18 patients with
pulmonary hypertension (8 with primary and 10 with throm-
boembolic pulmonary hypertension). NO gas (2,000 ppm in
nitrogen gas) was mixed with air with use of an originally
assembled apparatus that controlled each gas flow by comput-
erized mass flow meters (15). The mixture was then introduced
into a nonrebreathing circuit consisting of large bore tubing
and a continuous positive airway pressure mask. After a
complete baseline hemodynamic evaluation and blood sam-
pling for the measurement of plasma ANP and BNP, NO at 80
ppm was inhaled for 10 min. Subsequently, the hemodynamic
evaluation and blood sampling were repeated. Patients were
classified as responders and nonresponders on the basis of
hemodynamic responses to the NO trial. Responders were
defined as those whose total pulmonary resistance decreased
by .20% of the basal value (16). Eight patients were respond-
ers and 10 were nonresponders. Of the eight responders, two
had primary pulmonary hypertension and six had thromboem-
bolic pulmonary hypertension.
Effects of long-term hemodynamic changes on plasma ANP
and BNP levels. We examined nine patients with primary
pulmonary hypertension who underwent long-term vasodilator
therapy: 4 to 9 ng/kg per min of prostacyclin in four patients
and 5 to 12 ng/kg per min of prostaglandin E1 in five patients.
The mean follow-up period was 35 days (range 11 to 63). Right
heart catheterization and blood sampling for ANP and BNP
measurements were simultaneously performed before and
after these treatments.
Statistical analysis. All data were expressed as mean
value 6 SEM unless otherwise indicated. Log transformation
was used to normalize the distribution of plasma ANP and
BNP levels unless otherwise indicated. Comparisons of hemo-
dynamic data and cardiac function between RVVO and RVPO
groups were performed with the Student t test for unpaired
values. Comparisons of the mean values among the three
groups were made by using one-way analysis of variance
followed by the Scheffe´ multiple comparison test. To identify
relevant relations, linear regression analyses of hemodynamics
and cardiac function with plasma ANP or BNP were per-
formed. Those variables found to be significant in the linear
regression analysis were further examined by using multivari-
ate regression, and independent relations of hemodynamics
and cardiac function with plasma ANP or BNP were deter-
mined. The effects of vasodilator therapy on plasma ANP and
BNP were analyzed with the Student t test for paired values. A
p value ,0.05 was considered statistically significant.
Results
Hemodynamic variables and cardiac function. The mean
pulmonary artery pressure, total pulmonary resistance, mean
right atrial pressure, RV end-diastolic pressure and RV myo-
cardial mass index were significantly higher in patients with
RVPO than with RVVO (Table 1). Cardiac output and RV
ejection fraction were significantly lower in patients with
RVPO. In contrast, RV end-diastolic volume index and right
atrial end-systolic volume index were significantly higher in
patients with RVVO than with RVPO. There were no signif-
icant differences between the two groups in pulmonary capil-
lary wedge pressure, mean systemic arterial pressure and in all
left-sided functional variables.
Plasma ANP and BNP levels. Plasma ANP levels were
significantly higher in patients with RVVO and RVPO than in
control subjects (Fig. 2A), and they tended to be higher in
patients with RVPO than in patients with RVVO (p 5 NS).
Plasma BNP levels were also significantly higher in patients
with RVVO or RVPO than in control subjects (Fig. 2B).
Elevations in plasma BNP levels versus control values were
Table 1. Hemodynamic Variables and Cardiac Function in Patients
With Right Ventricular Overload
RVVO RVPO p Value*
mPAP (mm Hg) 22 6 4 52 6 3 , 0.001
CO (liters/min) 4.7 6 0.5 3.4 6 0.2 , 0.05
TPR (Wood U) 6 6 1 18 6 2 , 0.001
RAP (mm Hg) 4 6 1 8 6 1 , 0.01
RVEDP (mm Hg) 6 6 1 10 6 1 , 0.05
PCWP (mm Hg) 6 6 1 8 6 1 NS
mSAP (mm Hg) 82 6 8 80 6 5 NS
Qp/Qs 2.8 6 0.3 — —
RVEDVI (ml/m2) 165 6 14 104 6 6 , 0.001
RVEF (%) 45 6 2 31 6 2 , 0.01
RVMI (ml/m2) 26 6 3 43 6 4 , 0.05
RAESVI (ml/m2) 89 6 16 64 6 8 NS
LVEDVI (ml/m2) 56 6 4 63 6 4 NS
LVEF (%) 56 6 3 57 6 2 NS
LVMI (ml/m2) 55 6 2 57 6 3 NS
LAESVI (ml/m2) 52 6 4 36 6 2 NS
*RVVO versus RVPO. CO 5 cardiac output; LAESVI 5 left atrial
end-systolic volume index; LVEDVI 5 left ventricular end-diastolic volume
index; LVEF 5 left ventricular ejection fraction; LVMI 5 left ventricular
myocardial mass index; mPAP 5 mean pulmonary artery pressure; mSAP 5
mean systemic arterial pressure; PCWP 5 pulmonary capillary wedge pressure;
Qp/Qs 5 pulmonary to systemic flow ratio; RAESVI 5 right atrial end-systolic
volume index; RAP 5 mean right atrial pressure; RVEDP 5 right ventricular
end-diastolic pressure; RVEDVI 5 right ventricular end-diastolic volume index;
RVEF 5 right ventricular ejection fraction; RVMI 5 right ventricular myocar-
dial mass index; RVPO 5 right ventricular pressure overload due to primary or
thromboembolic pulmonary hypertension; RVVO 5 right ventricular volume
overload due to uncomplicated atrial septal defect; TPR 5 total pulmonary
resistance.
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more marked in patients with RVPO (;27-fold) than in those
with RVVO (;4-fold). The BNP/ANP ratio was also signifi-
cantly higher in patients with RVPO than in those with RVVO
or control subjects (Fig. 2C). Plasma ANP or BNP levels did
not show significant correlations with age or heart rate in the
patients studied (data not shown).
Relation between hemodynamic variables and plasma ANP
and BNP levels. Plasma ANP levels positively correlated with
mean pulmonary artery pressure and inversely with cardiac
output; therefore, they showed a strong positive correlation
with total pulmonary resistance (Table 2). Plasma ANP levels
also correlated positively with mean right atrial pressure and
RV end-diastolic pressure but not with pulmonary capillary
wedge pressure or mean systemic arterial pressure. Similarly,
plasma BNP levels correlated positively with mean pulmonary
artery pressure and inversely with cardiac output, thereby
showing a strong positive correlation with total pulmonary
resistance (Table 2, Fig. 3). Plasma BNP levels correlated
positively with mean right atrial pressure and RV end-diastolic
pressure but not with pulmonary capillary wedge pressure or
mean systemic arterial pressure.
Relation between cardiac function and plasma ANP and
BNP levels. Plasma ANP levels correlated inversely with RV
ejection fraction and positively with RV myocardial mass index
(Table 2). However, there were no significant correlations
between plasma ANP levels and RV end-diastolic volume
index, right atrial end-systolic volume index, LV ejection
fraction, LV end-diastolic volume index, LV myocardial mass
index or left atrial end-systolic volume index. Plasma BNP
levels correlated inversely with RV ejection fraction and
positively with RV myocardial mass index, but there were no
significant correlations between plasma BNP levels and RV
end-diastolic volume index, right atrial end-systolic volume
index, LV ejection fraction, LV end-diastolic volume index, LV
myocardial mass index or left atrial end-systolic volume index
(Table 2, Fig. 4). The four patients who were excluded from
the CT study because of severe RV dysfunction had markedly
poor hemodynamics and high plasma levels of ANP and BNP
(mean pulmonary artery pressure 66 6 9 mm Hg, cardiac
output 2.1 6 0.1 liters/min, total pulmonary resistance 31 6 5
Figure 2. Bar graph showing plasma levels of ANP (A) and BNP (B) and
the BNP/ANP (C) ratio in control subjects (Cont.) and patients with
RVVO and RVPO. *p , 0.05 versus control. †p , 0.05 versus RVVO. Figure 3. A, Correlation between plasma BNP levels and total pulmo-
nary resistance (TPR) in patients with RV overload. B, Correlation
between plasma BNP levels and RV end-diastolic pressure (RVEDP).
Squares 5 primary pulmonary hypertension; circles 5 thromboem-
bolic pulmonary hypertension; triangles 5 atrial septal defect.
Figure 4. A, Correlation between plasma brain natriuretic peptide
(BNP) levels and right ventricular ejection fraction (RVEF) in patients
with right ventricular overload. B, Correlation between plasma brain
natriuretic peptide (BNP) levels and right ventricular end-diastolic
volume index (RVEDVI). NS 5 not significant. Squares 5 primary
pulmonary hypertension; circles 5 thromboembolic pulmonary hyper-
tension; triangles 5 atrial septal defect.
Table 2. Correlation Coefficients Between Natriuretic Peptide
Levels and Hemodynamic or Cardiac Functional Variables
Variable
ANP (log values) BNP (log values)
r Coeff p Value r Coeff p Value
mPAP 0.70 , 0.001 0.73 , 0.001
CO 20.34 , 0.05 20.33 , 0.05
TPR 0.75 , 0.001 0.79 , 0.001
RAP 0.75 , 0.001 0.79 , 0.001
RVEDP 0.78 , 0.001 0.76 , 0.001
PCWP 0.08 NS 0.26 NS
mSAP 0.08 NS 0.00 NS
RVEDVI 0.30 NS 0.12 NS
RVEF 20.60 , 0.001 20.71 , 0.001
RVMI 0.71 , 0.001 0.71 , 0.001
RAESVI 0.31 NS 0.33 NS
LVEDVI 20.04 NS 0.00 NS
LVEF 20.27 NS 20.22 NS
LVMI 20.28 NS 20.28 NS
LAESVI 0.24 NS 0.17 NS
Coeff 5 coefficient; other abbreviations as in Table 1.
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Wood U, RV end-diastolic pressure 20 6 2 mm Hg, mean right
atrial pressure 18 6 2 mm Hg, ANP 520 6 165 pg/ml and BNP
878 6 162 pg/ml).
Multivariate analysis. As previously described, univariate
analyses demonstrated significant correlations of mean pulmo-
nary artery pressure, cardiac output, total pulmonary resis-
tance, mean right atrial pressure, RV end-diastolic pressure,
RV ejection fraction or RV myocardial mass index with plasma
ANP and BNP levels. Mean pulmonary artery pressure, car-
diac output, mean right atrial pressure, RV end-diastolic
pressure, RV ejection fraction and RV myocardial mass index,
excluding total pulmonary resistance, were examined as inde-
pendent factors because total pulmonary resistance is a vari-
able derived from mean pulmonary artery pressure and cardiac
output. Among these variables, mean right atrial pressure and
RV end-diastolic pressure correlated independently with
plasma ANP levels (p , 0.05). RV end-diastolic pressure and
RV ejection fraction correlated independently with plasma
BNP levels (p , 0.05).
Effects of acute hemodynamic changes on plasma ANP and
BNP levels. In responders, plasma ANP levels decreased
significantly after inhalation of NO (121 6 41 to 55 6 23 pg/ml,
Fig. 5A). In contrast, plasma BNP levels were not signifi-
cantly altered even after NO inhalation (208 6 126 to 194 6
122 pg/ml, Fig. 5B). Nonresponders showed no significant
changes in plasma ANP (206 6 58 to 194 6 50 pg/ml) or BNP
(321 6 98 to 329 6 97 pg/ml).
Effects of long-term hemodynamic changes on plasma ANP
and BNP levels. After long-term vasodilator treatment, total
pulmonary resistance decreased in all patients with pulmonary
hypertension (23 6 4 to 15 6 3 Wood U, p , 0.05). Plasma
ANP levels were reduced from 148 6 34 to 72 6 21 pg/ml (p ,
0.05), and plasma BNP levels from 315 6 120 to 144 6 54
pg/ml (p , 0.05). The decrease in plasma ANP and in plasma
BNP showed significant correlations with the decrease in total
pulmonary resistance (Fig. 6).
Comparison of plasma ANP and BNP levels between the
pulmonary artery and femoral vein. Both plasma ANP and
BNP levels revealed close correlations between the samples
from the main pulmonary artery and those from the femoral
vein (ANP, r 5 0.96, p , 0.001; BNP, r 5 0.99, p , 0.001),
although the plasma levels were higher in the main pulmonary
artery than in the femoral vein (ANP, 130 6 29 vs. 80 6 15
pg/ml; BNP, 193 6 46 vs. 155 6 36 pg/ml, p , 0.05).
Discussion
In this study, we demonstrated for the first time 1) that both
plasma BNP and ANP levels were elevated in RV overload,
particularly the plasma BNP levels elevated in RV pressure
overload, and 2) that plasma BNP levels correlated positively
with mean pulmonary artery pressure, total pulmonary resis-
tance, mean right atrial pressure, RV end-diastolic pressure
and RV myocardial mass index; and correlated negatively with
cardiac output and RV ejection fraction, whereas plasma BNP
levels did not correlate significantly with any LV variables.
Finally, we demonstrated 3) that plasma BNP levels changed in
association with long-term changes in hemodynamics, thereby
serving as a potential indicator of the efficacy of long-term
vasodilator treatment in patients with pulmonary hypertension.
Plasma BNP in RV overload. ANP is released mainly from
atrial tissue in healthy subjects, although it is also secreted
from ventricular tissue in patients with ventricular disorders. In
contrast, BNP is secreted predominantly from ventricular
tissue (1,2). BNP messenger ribonucleic acid (RNA) can be
detected not only in the LV but also in the RV of normal
human cardiac tissues obtained at autopsy (17). These findings
raise the possibility that different types of overload of the left
or right atria or ventricles, or both, may result in differing
secretion patterns of ANP and BNP. In fact, plasma BNP
levels have been shown to be elevated in patients with LV
overload in proportion to the degree of LV dysfunction (4) or
LV hypertrophy (5).
In contrast, little information has previously been available
Figure 5. Changes in plasma levels of ANP (A) and BNP (B) in
patients with pulmonary hypertension who responded to a short-term
vasodilator trial with NO inhalation. Plasma ANP levels were signifi-
cantly decreased after inhalation, whereas plasma BNP levels re-
mained unchanged. PRE 5 before NO inhalation; POST 5 after NO
inhalation.
Figure 6. Relations between the decrease in total pulmonary resis-
tance (TPR) and the decrease in plasma levels of ANP (A) and BNP
(B) resulting from long-term vasodilator therapy in patients with
primary pulmonary hypertension. Both the decrease in plasma ANP
and that in plasma BNP correlated significantly with the decrease in
TPR.
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regarding plasma BNP levels in patients with isolated RV
overload. An experimental study (6) showed that BNP was
secreted mainly from the RV in hypoxic pulmonary hyperten-
sion. In humans, Lang et al. (18) showed that plasma BNP
levels were elevated in proportion to the degree of hypoxemia
in chronic obstructive pulmonary disease. They speculated that
BNP release was triggered by the increased pressure and
volume stress on the right side of the heart. However, RV
pressure and volume were not assessed in their study. Thus, the
mechanism of BNP secretion in RV overload remained to be
elucidated.
To examine the factors regulating BNP secretion in RV
overload, we assessed hemodynamic variables by cardiac cath-
eterization and ventricular volume, mass, and ejection fraction
by electron beam CT. Volume, mass and function of the RV
have been technically difficult to determine by conventional
methods because of its complex anatomic geometry. However,
electron beam CT made it possible to measure those RV
variables, and the reproducibility and accuracy of these CT
measurements have been validated in both animal and human
studies elsewhere (8,9).
In the present study, plasma BNP levels were correlated
with RV variables such as RV ejection fraction, RV end-
diastolic pressure and total pulmonary resistance. These re-
sults suggest that BNP secretion is influenced by the severity of
RV dysfunction in pulmonary hypertension.
Effects of acute and long-term hemodynamic changes on
BNP secretion. NO inhalation has been shown to produce
selective vasodilation of pulmonary vascular beds without
systemic effects because of the rapid inactivation of NO by
hemoglobin (19). Plasma ANP levels in responders decreased
significantly after NO inhalation, whereas plasma BNP levels
were unaltered. This difference may be attributed to the
different patterns of synthesis, secretion and clearance of ANP
versus BNP. ANP is released mainly from stored granules in
atrial tissue by way of a regulated pathway (20). In contrast,
BNP is secreted predominantly from cardiac ventricular tissue
by way of a constitutive pathway (2). In humans, ANP and BNP
have different plasma half-lives (ANP 3 min; BNP 20 min)
(21,22). Thus, plasma ANP is more likely than plasma BNP to
be affected by short-term hemodynamic changes. Plasma ANP
levels may be a marker for the efficacy of short-term vasodila-
tor trials, which have usually been performed in patients with
pulmonary hypertension to evaluate potential vasodilator re-
sponse (23,24).
We investigated the effects of long-term hemodynamic
unloading on plasma ANP and BNP levels in patients with
long-term vasodilator therapy. Both plasma ANP and BNP
levels, but particularly the latter, reflected the improvement in
total pulmonary resistance during long-term follow-up periods.
Thus, plasma BNP may be a potential marker for the efficacy
of long-term treatment for RV dysfunction.
Plasma ANP levels are easily influenced by blood pressure,
age, sodium intake, renal function, postural change and exer-
cise (25–29). In addition, increments in plasma ANP in pa-
tients with pulmonary hypertension are small compared with
those in plasma BNP. Thus, plasma ANP levels may be
significantly affected when blood samples are obtained in
nonstandardized settings. In contrast, plasma BNP levels are
not easily affected by postural changes or exercise. Therefore,
plasma BNP may be more suitable than ANP for the evalua-
tion of the pathophysiology of pulmonary hypertension.
Pathophysiologic role of BNP in RV overload. The present
study showed that plasma BNP levels and the BNP/ANP ratio
were markedly elevated in patients with RVPO. BNP has been
reported (3,6) to have various biochemical effects such as
diuretic and natriuretic activities, potent vasodilator effects
both for pulmonary and systemic circulation and suppression
of aldosterone secretion. These findings suggest that BNP may
play an important role in maintaining cardiopulmonary ho-
meostasis in RV overload through a reduction in preload and
afterload. Recently, Pidgeon et al. (30) demonstrated that the
natriuretic and blood pressure–lowering effects of BNP are two
to three times as powerful as those of equal amounts of ANP.
In view of the strong biologic effects of BNP, the dispropor-
tionate elevation of BNP over ANP in patients with RVPO
may represent a compensatory mechanism under conditions
such as severe right heart failure due to pulmonary hyperten-
sion.
Study limitations. 1) Four patients were excluded from the
CT study because of severe RV dysfunction. However, inclu-
sion of these patients should not have affected the conclusions
drawn from our data, because all four had markedly poor
hemodynamic status and high plasma levels of ANP and BNP.
2) It would be interesting to investigate changes in RV ejection
fraction associated with long-term vasodilator therapy in pa-
tients with primary pulmonary hypertension. However, we
could not repeat the CT study in the follow-up period because
of the potential side effects of repeated examinations in
patients with severe pulmonary hypertension. 3) The useful-
ness of plasma BNP as a marker for RV dysfunction still needs
to be validated in a longitudinal large-scale study.
Conclusions. Plasma BNP levels increase in proportion to
the extent of RV dysfunction in pulmonary hypertension.
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